TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 24154863
Drug: High-dose clopidogrel
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose clopidogrel (900 mg loading dose / 150 mg daily maintenance dose)
Study: 23034424
Drug: Toothbrushing and
Normalized name: monofluorophosphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Toothbrushing and tongue cleaning with tooth-and-tongue gel
Study: 20854964
Drug: Antihypertensive therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antihypertensive therapy (losartan or atenolol)
Study: 20854964
Drug: Normal in-treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal in-treatment transmitral flow pattern
Study: 11185631
Drug: Telmisartan 120
Normalized name: Telmisartan
DrugBank: Telmisartan (DB00966)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Telmisartan 120 mg
Study: 27612991
Drug: Doxapram dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxapram dosing adjusted for gender and postmenstrual age (GrA)
Study: 27612991
Drug: Doxapram dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxapram dosing based on infants' weight alone (GrW)
Study: 22248750
Drug: Lactate Ringer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactate Ringer solution (RL)
Study: 3540872
Drug: Meperidine 50
Normalized name: meperidine 50 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meperidine 50 mg
Study: 10462387
Drug: Consensus interferon
Normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Consensus interferon (9 microg) given three times weekly for 24 weeks
Study: 10462387
Drug: Interferon alfa‐2b
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon alfa‐2b (3 million units) given three times weekly for 24 weeks
Study: 2195704
Drug: 6 g
Normalized name: FAPi-46 GA-68
DrugBank: FAPi-46 GA-68 (DB18827)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 g Almarin capsules (fish oil concentrate) daily for 12 weeks
Study: 23359185
Drug: HDC +
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: HDC + DC/CIK (120 mg/m(2) docetaxel, 175 mg/m(2) thiotepa, with or without 400 mg/m(2) carboplatin)
Study: 23359185
Drug: Standard dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dose chemotherapy (SDC) (75 mg/m(2) docetaxel and 75 mg/m(2) thiotepa)
Study: 12584829
Drug: Sanjin tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sanjin tablet
Study: 22097348
Drug: Conventional sensitive
Normalized name: Fluorimax Sensitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional sensitive antibiotics
Study: 16685007
Drug: Ciclesonide treatment
Normalized name: Ciclesonide
DrugBank: Ciclesonide (DB01410)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ciclesonide treatment groups
Study: 8204277
Drug: Sucralfate cream
Normalized name: Sucralfate
DrugBank: Sucralfate (DB00364)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sucralfate cream
Study: 15542162
Drug: No cream
Normalized name: Oil, Multi Ingredient Topical application Oil [AVEENO CREAMY MOISTURIZING OIL]
DrugBank: Nitric Oxide (DB00435)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: No cream (control)
Study: 11380297
Drug: hCG on
Approvals — FDA: no, EMA: no, PMDA: no
Description: hCG on the day of embryo transfer + daily vaginal progesterone (group II)
Study: 11380297
Drug: hCG in
Approvals — FDA: no, EMA: no, PMDA: no
Description: hCG in combination with daily vaginal progesterone (group IV)
Study: 11380297
Drug: hCG only
Approvals — FDA: no, EMA: no, PMDA: no
Description: hCG only or additional injection of hCG
Study: 9233866
Drug: Radiotherapy plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiotherapy plus goserelin (3.6 mg subcutaneously every four weeks for three years)
Study: 7654898
Drug: Pravastatin (20-40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pravastatin (20-40 mg) with hypolipemiant dietetic treatment
Study: 7654898
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (dietetic treatment only)
Study: 26945818
Drug: Ropivacaine 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine 40 ml
Study: 21087499
Drug: Propranolol added
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol added to standard treatment
Study: 14501856
Drug: Intraoperative Thymoglobulin
Normalized name: Thymoglobulin
DrugBank: Antithymocyte immunoglobulin (rabbit) (DB00098)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraoperative Thymoglobulin (1 mg/kg/dose, 3 to 6 doses during the first week posttransplant)
Study: 14501856
Drug: Postoperative Thymoglobulin
Normalized name: Thymoglobulin
DrugBank: Antithymocyte immunoglobulin (rabbit) (DB00098)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative Thymoglobulin (1 mg/kg/dose, 3 to 6 doses during the first week posttransplant)
Study: 10434160
Drug: Venlafaxine (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Venlafaxine (200 to 300 mg/day)
Study: 10434160
Drug: Paroxetine (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paroxetine (30 to 40 mg/day)
Study: 8794438
Drug: E3 (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: E3 (0.5 mg every other day) + Ca (0.5 g/day)
Study: 9212355
Drug: Low Molecular
Normalized name: Low molecular weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low Molecular Weight Heparin (LMWH)
Study: 6352626
Drug: Ceftazidime 2
Normalized name: ceftazidime 2000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftazidime 2 g iv dose
Study: 26037521
Drug: Vitamin D3
Normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D3 supplementation (20 μg/d)
Study: 24675102
Drug: Parenteral corticosteroid
Normalized name: abiraterone and corticosteroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parenteral corticosteroid (PS) (n=33)
Study: 24675102
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg nebulized steroid (NB) (n=27)
Study: 24675102
Drug: 8 mg
Normalized name: alloin 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 mg nebulized steroid (NB) (n=26)
Study: 17919549
Drug: Goserelin acetate
Normalized name: Goserelin Acetate
DrugBank: Goserelin (DB00014)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Goserelin acetate 10.8 mg plus iron (ferrous sulfate 325 mg TID)
Study: 17919549
Drug: Sham (iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham (iron monotherapy)
Study: 12074599
Drug: Vitamin C
Normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin C supplementation (250 mg/day for six weeks)
Study: 10335420
Drug: Propranolol (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (20 mg for weeks 1 and 2, 30 mg for weeks 3 and 4, twice daily)
Study: 6749996
Drug: EB-FITC combination
Normalized name: Folate-FITC
DrugBank: EC-17 (DB12559)
Approvals — FDA: no, EMA: no, PMDA: no
Description: EB-FITC combination
Study: 6749996
Drug: PI-FITC combination
Normalized name: PI-103
DrugBank: PI-103 (DB17046)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PI-FITC combination
Study: 6749996
Drug: DAPI-TRITC combination
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: DAPI-TRITC combination
Study: 29986268
Drug: Pill counts
Normalized name: oteseconazole
DrugBank: Oteseconazole (DB13055)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pill counts (self-reported adherence)
Study: 28427456
Drug: Surgery with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgery with atrial natriuretic peptide (ANP) administration for 3 days during the perioperative period
Study: 24125415
Drug: Beetroot juice
Normalized name: tamarind juice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beetroot juice (140 mL providing approximately 500 mg dietary nitrate)
Study: 14613435
Drug: Inhaled corticosteroids
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled corticosteroids (ICSs) as maintenance treatment for persistent asthma
Study: 14613435
Drug: Addition of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Addition of a long-acting inhaled beta2-agonist or a leukotriene modifier to ICS therapy
Study: 27719743
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg LCZ696 after low-fat meal
Study: 27719743
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg LCZ696 after high-fat meal
Study: 27719743
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg LCZ696 under fasting condition
Study: 24978674
Drug: Testosterone treatment
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone treatment (im testosterone undecanoate) for 40 weeks
Study: 23484301
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment (direct restoration)
Study: 18259825
Drug: Neoadjuvant therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant therapy for pancreatic cancer
Study: 18259825
Drug: Adjuvant therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant therapy for pancreatic cancer
Study: 10959482
Drug: Lamivudine (100-150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lamivudine (100-150 mg daily)
Study: 2861759
Drug: Pancuronium (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pancuronium (80 micrograms/kg iv) in patients pretreated with beta-receptor blockers and receiving fentanyl (7 micrograms/kg)
Study: 2861759
Drug: Pancuronium (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pancuronium (80 micrograms/kg iv) in patients not on preoperative beta-receptor blocker medication
Study: 31851172
Drug: Cortexin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cortexin (10 days, once daily intramuscularly)
Study: 23739513
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no pharmacotherapy)
Study: 25026806
Drug: Adaptol (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adaptol (3 tablets, 1500 mg daily)
Study: 25026806
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment (disintoxication therapy, prednisolone 30‐60 mg/day, antihistamines, phototherapy, topical steroids, topical emollients)
Study: 22494062
Drug: I-gel(TM) laryngeal
Normalized name: iobenguane I-131
Approvals — FDA: no, EMA: no, PMDA: no
Description: I-gel(TM) laryngeal mask airway with sevoflurane
Study: 22494062
Drug: I-gel(TM) laryngeal
Normalized name: iobenguane I-131
Approvals — FDA: no, EMA: no, PMDA: no
Description: I-gel(TM) laryngeal mask airway with desflurane
Study: 21038653
Drug: BAI with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: BAI with oleum fructus bruceae (OFB) + chemotherapeutic agents (CTA)
Study: 21038653
Drug: BAI with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: BAI with chemotherapeutic agents (CTA) alone
Study: 16398771
Drug: Rectal misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rectal misoprostol (400 microg) and intravenous oxytocin (10 IU/hour)
Study: 8794822
Drug: Losartan (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan (50 mg QD)
Study: 8794822
Drug: Metoprolol (95
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol (95 mg QD)
Study: 6391153
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg SAMe per os tid during oral contraceptive treatment
Study: 6391153
Drug: Oral contraceptives
Normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral contraceptives containing 50 micrograms ethynylestradiol plus 250 micrograms d-norgestrel
Study: 29354952
Drug: Autologous blood
Normalized name: Banked autologous blood
Approvals — FDA: no, EMA: no, PMDA: no
Description: Autologous blood injection at Zusanli (ST 36)
Study: 21570271
Drug: 9 g
Normalized name: Publix Pen Needle 29 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 9 g brewer's yeast (42 μg Cr) daily for 3 months
Study: 10856732
Drug: eprosartan (540+/‐96
Approvals — FDA: no, EMA: no, PMDA: no
Description: eprosartan (540+/‐96 mg/day)
Study: 8985221
Drug: Polysaccharide vaccine
Normalized name: Typhoid Vi polysaccharide vaccine
DrugBank: Typhoid Vi polysaccharide vaccine (DB10803)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polysaccharide vaccine
Study: 1588148
Drug: PRP-D vaccine
Normalized name: Hib (PRP-D)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PRP-D vaccine (polysaccharide conjugated to diphtheria toxoid)
Study: 1588148
Drug: HbOC vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HbOC vaccine (oligosaccharide conjugated to CRM197 protein)
Study: 29027352
Drug: Donor dopamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Donor dopamine treatment
Study: 24737923
Drug: Anti-inflammatory therapy
Normalized name: Surpass Anti-Inflammatory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-inflammatory therapy after surgery
Study: 24737923
Drug: No anti-inflammatory
Normalized name: Surpass Anti-Inflammatory
Approvals — FDA: no, EMA: no, PMDA: no
Description: No anti-inflammatory therapy after surgery
Study: 24417929
Drug: Aspirin group
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin group (continued aspirin, discontinued clopidogrel at least 5 days before surgery)
Study: 24417929
Drug: Aspirin and
Normalized name: Aspirin and Caffeine Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin and clopidogrel group (had both until 3 days before surgery)
Study: 24417929
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (discontinued antiplatelet therapy 5 days before surgery)
Study: 18179713
Drug: Olanzapine (5-20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olanzapine (5-20 mg/day) for bipolar mania
Study: 18179713
Drug: Olanzapine (10-20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olanzapine (10-20 mg/day) for schizophrenia
Study: 16794788
Drug: Carvedilol (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carvedilol (5 mg twice per day, increased to maximum tolerated dose)
Study: 16794788
Drug: Metoprolol tartrate
Normalized name: Metoprolol Tartrate
DrugBank: Metoprolol (DB00264)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Metoprolol tartrate (20 mg three times per day, increased to maximum tolerated dose)
Study: 12084605
Drug: Omapatrilat 40
Normalized name: OMAPATRILAT
DrugBank: Omapatrilat (DB00886)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omapatrilat 40 mg
Study: 12084605
Drug: Omapatrilat 20
Normalized name: OMAPATRILAT
DrugBank: Omapatrilat (DB00886)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omapatrilat 20 mg
Study: 10637684
Drug: Pharmacological treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacological treatment (methylphenidate or placebo)
Study: 10637684
Drug: Nonpharmacological treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonpharmacological treatment (parent groups: training or support)
Study: 1975189
Drug: Esmolol (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esmolol (100 mg and 200 mg)
Study: 7270984
Drug: Albuterol syrup
Normalized name: Albuterol
DrugBank: Albuterol (DB01001)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albuterol syrup
Study: 24608079
Drug: Higher dose
Normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher dose intravenous methotrexate (MTX) 2.5 g/m
Study: 24608079
Drug: Standard dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dose intravenous methotrexate (MTX) 1 g/m
Study: 24608079
Drug: High-dose cytosine
Normalized name: cytosine
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose cytosine arabinoside/asparaginase
Study: 23012385
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg intravenous doripenem
Study: 23012385
Drug: 1000 mg
Normalized name: bran 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mg intravenous doripenem
Study: 20212271
Drug: Perindopril-based blood
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perindopril-based blood pressure-lowering therapy
Study: 15141263
Drug: Acetaminophen 650
Normalized name: acetaminophen 650 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen 650 mg per rectum every 4 hours
Study: 12667363
Drug: Calcium carbonate
Normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcium carbonate (Ca) 400 mg/d + vitamin D 200 IU/D (Control group)
Study: 12667363
Drug: E(2)V 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: E(2)V 1.0 mg/d + MPA 2 mg/d + Ca 400 mg/d (Treatment group 1)
Study: 12667363
Drug: E(2)V 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: E(2)V 1.0 mg/d + MPA 2 mg/d + Ca 400 mg/d + vitamin D 200 IU/d (Treatment group 2)
Study: 12667363
Drug: E(2)V 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: E(2)V 1.5 mg/d + MPA 2 mg/d + Ca 400 mg/d + vitamin D 200 IU/d (Treatment group 3)
Study: 7818118
Drug: 3 mL
Normalized name: WATER,INHL 3 ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mL of 1.5% lidocaine with epinephrine (1:200,000) IV
Study: 7818118
Drug: 3 mL
Normalized name: WATER,INHL 3 ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mL of normal saline IV
Study: 1703451
Drug: Carboplatin 300
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Carboplatin 300 mg/m2 and fluoro‐uracil 1000 mg/m2/d administered in continuous IV infusion for 96 h every 4 weeks (group 1)
Study: 1703451
Drug: Carboplatin 350
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Carboplatin 350 mg/m2 and fluoro‐uracil administered at the same dose every 3 weeks (group II)
Study: 1703451
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups (combined therapy with carboplatin and fluoro‐uracil)
Study: 28446631
Drug: Balanced protein‐energy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Balanced protein‐energy supplementation of 500 mL milk/d plus a 10‐μg vitamin B‐12 tablet/d (M+B‐12 group)
Study: 28446631
Drug: Milk (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Milk (500 mL/d) plus a placebo tablet (M+P group)
Study: 28446631
Drug: Placebo tablet
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablet alone (P group)
Study: 17978289
Drug: S-1 (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: S-1 (80 mg/m²/day for 4 weeks followed by 2 weeks off, for 1 year)
Study: 8160603
Drug: Sequential monophasic
Normalized name: Monobasic Potassium Phosphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential monophasic shocks
Study: 6084754
Drug: Tamoxifen (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamoxifen (20 mg b.i.d. for 10 days)
Study: 25288348
Drug: Intra-articular glucocorticoid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-articular glucocorticoid injection (40 mg triamcinolone acetonide)
Study: 26654244
Drug: Single 300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single 300 ml dose of anthocyanin-rich cherry juice
Study: 26654244
Drug: 3 x
Normalized name: Xenon (133 xe)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 x 100 ml doses of anthocyanin-rich cherry juice
Study: 23828481
Drug: Endobronchial valve
Normalized name: VALVE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endobronchial valve therapy (EBV)
Study: 17690310
Drug: Conservative therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative therapy (control)
Study: 20820148
Drug: Fenoldopam 0.05-mcg/kg/min
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenoldopam 0.05-mcg/kg/min
Study: 19127796
Drug: Short-term amoxicillin-clavulanic
Normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Short-term amoxicillin-clavulanic acid
Study: 19127796
Drug: Long-term amoxicillin-clavulanic
Normalized name: amoxicillin / clavulanate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long-term amoxicillin-clavulanic acid
Study: 17085378
Drug: Sequential oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential oral and transdermal estradiol regimen (2 mg oral micronized 17beta‐estradiol/day or 1.5 mg 17beta‐estradiol gel/day) combined with oral dydrogesterone (10 mg/day, 12 days/month) for 1 year
Study: 1796408
Drug: Heparin intravenously
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin intravenously 30,000-40,000 U daily
Study: 21406956
Drug: Cognitive stimulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive stimulation intervention for 2 months, weekly group sessions.
Study: 10500058
Drug: Ibuprofen (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen (800 mg 3 times daily)
Study: 12600812
Drug: Tiagabine (add-on
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiagabine (add-on therapy)
Study: 10368798
Drug: Goserelin 3.6
Normalized name: goserelin 3.6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Goserelin 3.6 mg implant four weekly + placebo tablets daily (Group C)
Study: 10368798
Drug: Goserelin 3.6
Normalized name: goserelin 3.6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Goserelin 3.6 mg implant four weekly + estradiol valerate 2 mg daily with norethisterone 5 mg from days 21-28 of a 28-day cycle (Group B)
Study: 10368798
Drug: Placebo implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo implant four weekly + placebo tablets daily (Group A)
Study: 8897354
Drug: 5,6 benzo‐[alpha]‐pyrone
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5,6 benzo‐[alpha]‐pyrone (coumarin 400 mg/day) for six months
Study: 8897354
Drug: Heat therapy
Normalized name: CVS Neck Arm & Leg Heat Therapy Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heat therapy (microwave) plus compression garments for six months
Study: 8897354
Drug: Benzopyrones for
Normalized name: benzopyrene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benzopyrones for 12 months plus heat treatment for six months
Study: 8897354
Drug: Heat therapy
Normalized name: CVS Neck Arm & Leg Heat Therapy Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heat therapy plus either placebo or benzopyrone
Study: 6711782
Drug: 0.4 mg
Normalized name: biotin 0.4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.4 mg buprenorphine pre‐emptively for postoperative pain
Study: 6711782
Drug: Morphine or
Normalized name: morphine Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine or placebo
Study: 28993346
Drug: Immediate active
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate active treatment with intravenous abatacept